High ROIC Stocks
UTHR is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
UNITED THERAPEUTICS CORP (UTHR) Stock Price & Overview
NASDAQ:UTHR • US91307C1027
Current stock price
564.81 USD
-5.46 (-0.96%)
At close:
564.23 USD
-0.58 (-0.1%)
After Hours:
The current stock price of UTHR is 564.81 USD. Today UTHR is down by -0.96%. In the past month the price increased by 16.44%. In the past year, price increased by 93.12%.
UTHR Key Statistics
52-Week Range266.98 - 607.89
Current UTHR stock price positioned within its 52-week range.
1-Month Range471.29 - 607.89
Current UTHR stock price positioned within its 1-month range.
- Market Cap
- 24.756B
- P/E
- 20.24
- Fwd P/E
- 18.91
- EPS (TTM)
- 27.90
- Dividend Yield
- N/A
UTHR Stock Performance
Today
-0.96%
1 Week
+6.06%
1 Month
+16.44%
3 Months
+13.71%
Longer-term
6 Months +24.66%
1 Year +93.12%
2 Years +141.03%
3 Years +145.43%
5 Years +180.22%
10 Years +436.89%
UTHR Stock Chart
UTHR Stock Screens
UTHR currently appears in the following ChartMill screener lists.
UTHR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to UTHR. When comparing the yearly performance of all stocks, UTHR is one of the better performing stocks in the market, outperforming 90% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
UTHR Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to UTHR. UTHR scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
UTHR Earnings
On February 25, 2026 UTHR reported an EPS of 7.7 and a revenue of 790.20M. The company beat EPS expectations (5.05% surprise) and missed revenue expectations (-4.72% surprise).
Next Earnings DateApr 28, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$7.70
Revenue Reported790.2M
EPS Surprise 5.05%
Revenue Surprise -4.72%
UTHR Forecast & Estimates
21 analysts have analysed UTHR and the average price target is 603.09 USD. This implies a price increase of 6.78% is expected in the next year compared to the current price of 564.81.
For the next year, analysts expect an EPS growth of 7.05% and a revenue growth 4.32% for UTHR
Analysts
Analysts81.9
Price Target603.09 (6.78%)
EPS Next Y7.05%
Revenue Next Year4.32%
UTHR Groups
Sector & Classification
UTHR Financial Highlights
Over the last trailing twelve months UTHR reported a non-GAAP Earnings per Share(EPS) of 27.9. The EPS increased by 13.41% compared to the year before.
Income Statements
Revenue(TTM)3.18B
Net Income(TTM)1.33B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.94% | ||
| ROA | 16.94% | ||
| ROE | 18.81% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%24.39%
Sales Q2Q%7.38%
EPS 1Y (TTM)13.41%
Revenue 1Y (TTM)10.61%
UTHR Ownership
Ownership
Inst Owners98.05%
Shares43.83M
Float42.93M
Ins Owners1.81%
Short Float %6.63%
Short Ratio5.85
UTHR Latest News, Press Relases and Analysis
6 days ago - By: Chartmill
UTHR Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About UTHR
Company Profile
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Company Info
IPO: 1999-06-17
UNITED THERAPEUTICS CORP
1000 Spring St
Silver Spring MARYLAND 20910 US
CEO: Martine A. Rothblatt
Employees: 1400
Phone: 13016089292
UNITED THERAPEUTICS CORP / UTHR FAQ
What does UTHR do?
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
What is the stock price of UNITED THERAPEUTICS CORP today?
The current stock price of UTHR is 564.81 USD. The price decreased by -0.96% in the last trading session.
Does UNITED THERAPEUTICS CORP pay dividends?
UTHR does not pay a dividend.
What is the ChartMill rating of UNITED THERAPEUTICS CORP stock?
UTHR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the expected growth for UTHR stock?
The Revenue of UNITED THERAPEUTICS CORP (UTHR) is expected to grow by 4.32% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for UTHR stock?
UNITED THERAPEUTICS CORP (UTHR) will report earnings on 2026-04-28, before the market open.
Can you provide the short interest for UTHR stock?
The outstanding short interest for UNITED THERAPEUTICS CORP (UTHR) is 6.63% of its float.